research Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia
New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
Search
for
Sort by
Research
720-750 / 1000+ results 
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Probing androgen receptor co-factor selectivity profiles: a chemical tool to determine cross-talk between androgen receptor and β-catenin in vivo
PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
research A distinct cutaneous reaction to sorafenib and a multikinase inhibitor
Sorafenib can cause a unique skin reaction.
research Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride
Using finasteride or dutasteride does not increase the risk of male breast cancer.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer
Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
research 5α-Reductase: History and Clinical Importance
5α-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT levels.
research Finasteride < Rec INN; BAN; USAN >
research RE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER
Dutasteride may help shrink prostate cancer tumors.
research TGF-β Signaling: a Potential Therapeutic Target of Single Herbs and Extracts for Renal Fibrosis
Certain Chinese herbs may help treat kidney fibrosis by targeting TGF-β.
research Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor
Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.
![Synthesis and In Vitro Study of 17β-[N-Ureylene-N,N′-Disubstituted]-4-Methyl-4-Aza-5α-Androstan-3-Ones as Selective Inhibitors of Type I 5α-Reductase](/images/research/d19df8a7-8de6-4430-8a0d-4ffa1f502985/small/15608.jpg)
research Synthesis and in vitro study of 17β-[N-ureylene-N,N′-disubstituted]-4-methyl-4-aza-5α-androstan-3-ones as selective inhibitors of type I 5α-reductase
New compounds were made that effectively block a specific enzyme related to androgen conditions.
research 5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection
5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction, but the exact reasons are unclear.
research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research Prostate cancer update: 2007
2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
research Louisiana Marinas and Boat Launches, LOSCO (2003) [marinas]
Finasteride, selenium, and vitamin E may help prevent prostate cancer.
research 455 Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata
Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
research Alopecia universalis. Partial response to tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
research Hormonal manipulation with finasteride or oral contraception does not influence incidence of renal cell carcinoma
research Old drug new indication: Tofacitinib for a new crop of hair?
Tofacitinib might be used to treat hair loss.
research Alopecia universalis successfully treated with tofacitinib
Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research Experimental Evaluation of 3-meta-Pyridine-1,2,4-Oxadiazole Derivative of Deoxycholic Acid as a Prototype of 5-α-Reductase Inhibitors in In Silico and In Vivo Models
The new compound may be a safer alternative to finasteride for prostate protection.
research USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research New treatments for rheumatoid arthritis
New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
research An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
research Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.